Brief: Sarepta Announces That Screening And Enrollment Are Underway In Endeavor Cohort 8 To Evaluate Enhanced Immunosuppression Regimen As Part Of Elevidys Gene Therapy For Non-Ambulant Individuals With Duchenne
16/03/2026 12:39
March 16 (Reuters) - Sarepta Therapeutics Inc SRPT.O: SAREPTA ANNOUNCES THAT SCREENING AND ENROLLMENT ARE UNDERWAY IN ENDEAVOR COHORT 8 TO EVALUATE ENHANCED IMMUNOSUPPRESSION REGIMEN AS PART OF ELEVIDYS GENE THERAPY FOR NON-AMBULANT INDIVIDUALS WITH DUCHENNE Source text: ID:nBw3Rm3gga Further company coverage: SRPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure